“…The selection of doses of MPH was done according to previous work results on neurodegenerative doses of MPH in animal models and human subjects (Balcioglu, Ren, 2009, Gerasimov, Franceschi, 2000, Hannestad, Gallezot, 2010, Motaghinejad, Motevalian, 2015e, Quinn, Wigal, 2004, Schiffer, Volkow, 2006, Teo, Stirling, 2002, Thanos, Robison, 2015, Volkow, Wang, 2001, Wargin, Patrick, 1983, and neuroprotective doses of lithium was obtained from previous work on human and animal studies (Boyko, Nassar, 2015, Chrislip, Anger, 1984, Dhawan, Singh, 1999, Frey, Valvassori, 2006, Hajek and Weiner, 2016, Khairova, Pawar, 2012, Machado-Vieira, Manji, 2009, Rahimi, Dehpour, 2014, Rahimi_Balaei, Momeny, 2010. There are several references in relation to clinical relevance of choosing MPH and lithium doses in our experiment, and also the relationship that exist between doses and plasma levels in experimental subjects (Balcioglu, Ren, 2009, Hanak, Chevillard, 2014, Morrison, Pritchard, 1971, Severus, Kleindienst, 2007, Severus, Kleindienst, 2008, Teo, Stirling, 2002, Thanos, Robison, 2015, Wargin, Patrick, 1983 Elevated Plus Maze (EPM) was used to assess anxiety in animal models.…”